Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 125

1.

Two novel epigenetic pathways regulate NFE2 overexpression in myeloproliferative neoplasms.

Peeken JC, Jutzi JS, Wehrle J, Koellerer C, Staehle F, Becker H, Schoenwandt E, Seeger TS, Schanne DH, Gothwal M, Ott CJ, Gründer A, Pahl HL.

Blood. 2018 Mar 8. pii: blood-2017-10-810622. doi: 10.1182/blood-2017-10-810622. [Epub ahead of print]

PMID:
29519804
2.

Oncogenic JAK2V617F causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms.

Prestipino A, Emhardt AJ, Aumann K, O'Sullivan D, Gorantla SP, Duquesne S, Melchinger W, Braun L, Vuckovic S, Boerries M, Busch H, Halbach S, Pennisi S, Poggio T, Apostolova P, Veratti P, Hettich M, Niedermann G, Bartholomä M, Shoumariyeh K, Jutzi JS, Wehrle J, Dierks C, Becker H, Schmitt-Graeff A, Follo M, Pfeifer D, Rohr J, Fuchs S, Ehl S, Hartl FA, Minguet S, Miething C, Heidel FH, Kröger N, Triviai I, Brummer T, Finke J, Illert AL, Ruggiero E, Bonini C, Duyster J, Pahl HL, Lane SW, Hill GR, Blazar BR, von Bubnoff N, Pearce EL, Zeiser R.

Sci Transl Med. 2018 Feb 21;10(429). pii: eaam7729. doi: 10.1126/scitranslmed.aam7729.

PMID:
29467301
3.

Symptom burden profile in myelofibrosis patients with thrombocytopenia: Lessons and unmet needs.

Scotch AH, Kosiorek H, Scherber R, Dueck AC, Slot S, Zweegman S, Boekhorst PAWT, Commandeur S, Schouten H, Sackmann F, Fuentes AK, Hernández-Maraver D, Pahl HL, Griesshammer M, Stegelmann F, Döhner K, Lehmann T, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto JC, Ranta D, Roy L, Cahn JY, Harrison CN, Radia D, Muxi P, Maldonado N, Besses C, Cervantes F, Johansson PL, Barbui T, Barosi G, Vannucchi AM, Paoli C, Passamonti F, Andreasson B, Ferrari ML, Rambaldi A, Samuelsson J, Birgegard G, Xiao Z, Xu Z, Zhang Y, Sun X, Xu J, Kiladjian JJ, Zhang P, Gale RP, Mesa RA, Geyer HL.

Leuk Res. 2017 Dec;63:34-40. doi: 10.1016/j.leukres.2017.10.002. Epub 2017 Oct 14.

PMID:
29096334
4.

The oligodendrocyte lineage transcription factor 2 (OLIG2) is epigenetically regulated in acute myeloid leukemia.

Yalcin A, Kovarbasic M, Wehrle J, Claus R, Becker H, Abdelkarim M, Gaidzik VI, Schmidts A, Wäsch R, Pahl HL, Döhner K, Bullinger L, Duyster J, Lübbert M, Hackanson B.

Exp Hematol. 2017 Nov;55:76-85.e3. doi: 10.1016/j.exphem.2017.07.009. Epub 2017 Jul 28.

PMID:
28760688
5.

Tissue microarray technique is applicable to bone marrow biopsies of myeloproliferative neoplasms.

Limberger KA, Bogatyreva L, Todorova R, Herde B, Hauschke D, Pahl HL, Werner M, Aumann K.

Histochem Cell Biol. 2017 Jan;147(1):75-82. doi: 10.1007/s00418-016-1476-x. Epub 2016 Aug 20.

PMID:
27544663
6.

Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group.

Geyer HL, Kosiorek H, Dueck AC, Scherber R, Slot S, Zweegman S, Te Boekhorst PA, Senyak Z, Schouten HC, Sackmann F, Fuentes AK, Hernández-Maraver D, Pahl HL, Griesshammer M, Stegelmann F, Döhner K, Lehmann T, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto JC, Ranta D, Roy L, Cahn JY, Harrison CN, Radia D, Muxi P, Maldonado N, Besses C, Cervantes F, Johansson PL, Barbui T, Barosi G, Vannucchi AM, Paoli C, Passamonti F, Andreasson B, Ferrari ML, Rambaldi A, Samuelsson J, Cannon K, Birgegard G, Xiao Z, Xu Z, Zhang Y, Sun X, Xu J, Kiladjian JJ, Zhang P, Gale RP, Mesa RA.

Haematologica. 2017 Jan;102(1):85-93. doi: 10.3324/haematol.2016.149559. Epub 2016 Aug 18.

7.

A novel role for nuclear factor-erythroid 2 in erythroid maturation by modulation of mitochondrial autophagy.

Gothwal M, Wehrle J, Aumann K, Zimmermann V, Gründer A, Pahl HL.

Haematologica. 2016 Sep;101(9):1054-64. doi: 10.3324/haematol.2015.132589. Epub 2016 Jun 16.

8.

Immunohistochemical staining of transcription factor NFE2 for the discrimination of primary myelofibrosis from essential thrombocythemia.

Aumann K, Werner M, Pahl HL.

Hum Pathol. 2016 Jul;53:195-6. doi: 10.1016/j.humpath.2016.02.024. Epub 2016 Mar 30. No abstract available.

PMID:
27038682
9.

Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both.

Koschmieder S, Mughal TI, Hasselbalch HC, Barosi G, Valent P, Kiladjian JJ, Jeryczynski G, Gisslinger H, Jutzi JS, Pahl HL, Hehlmann R, Maria Vannucchi A, Cervantes F, Silver RT, Barbui T.

Leukemia. 2016 May;30(5):1018-24. doi: 10.1038/leu.2016.12. Epub 2016 Feb 8. Review.

PMID:
26854026
10.

Symptomatic Profiles of Patients With Polycythemia Vera: Implications of Inadequately Controlled Disease.

Geyer H, Scherber R, Kosiorek H, Dueck AC, Kiladjian JJ, Xiao Z, Slot S, Zweegman S, Sackmann F, Fuentes AK, Hernández-Maraver D, Döhner K, Harrison CN, Radia D, Muxi P, Besses C, Cervantes F, Johansson PL, Andreasson B, Rambaldi A, Barbui T, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto JC, Ranta D, Roy L, Cahn JY, Maldonado N, Barosi G, Ferrari ML, Gale RP, Birgegard G, Xu Z, Zhang Y, Sun X, Xu J, Zhang P, te Boekhorst PA, Commandeur S, Schouten H, Pahl HL, Griesshammer M, Stegelmann F, Lehmann T, Senyak Z, Vannucchi AM, Passamonti F, Samuelsson J, Mesa RA.

J Clin Oncol. 2016 Jan 10;34(2):151-9. doi: 10.1200/JCO.2015.62.9337. Epub 2015 Nov 23.

11.

The Hen or the Egg: Inflammatory Aspects of Murine MPN Models.

Jutzi JS, Pahl HL.

Mediators Inflamm. 2015;2015:101987. doi: 10.1155/2015/101987. Epub 2015 Oct 12. Review.

12.

Histone acetyltransferase inhibitors block neuroblastoma cell growth in vivo.

Gajer JM, Furdas SD, Gründer A, Gothwal M, Heinicke U, Keller K, Colland F, Fulda S, Pahl HL, Fichtner I, Sippl W, Jung M.

Oncogenesis. 2015 Feb 9;4:e137. doi: 10.1038/oncsis.2014.51.

13.

Phase I dose escalation study of lestaurtinib in patients with myelofibrosis.

Hexner EO, Mascarenhas J, Prchal J, Roboz GJ, Baer MR, Ritchie EK, Leibowitz D, Demakos EP, Miller C, Siuty J, Kleczko J, Price L, Jeschke G, Weinberg R, Basu T, Pahl HL, Orazi A, Najfeld V, Marchioli R, Goldberg JD, Silverman LR, Hoffman R.

Leuk Lymphoma. 2015;56(9):2543-51. doi: 10.3109/10428194.2014.1001986. Epub 2015 Feb 20.

14.

NFE2 regulates transcription of multiple enzymes in the heme biosynthesis pathway.

Rheinemann L, Seeger TS, Wehrle J, Pahl HL.

Haematologica. 2014 Oct;99(10):e208-10. doi: 10.3324/haematol.2014.106393. Epub 2014 Jun 20. No abstract available.

15.

Ponatinib: a third-generation inhibitor for the treatment of CML.

Wehrle J, Pahl HL, von Bubnoff N.

Recent Results Cancer Res. 2014;201:99-107. doi: 10.1007/978-3-642-54490-3_5. Review.

PMID:
24756787
16.

Many roads lead to MPN.

Pahl HL.

Blood. 2014 Apr 3;123(14):2133-4. doi: 10.1182/blood-2014-02-554709.

17.

The AML1/ETO target gene LAT2 interferes with differentiation of normal hematopoietic precursor cells.

Essig A, Duque-Afonso J, Schwemmers S, Pahl HL, Lübbert M.

Leuk Res. 2014 Mar;38(3):340-5. doi: 10.1016/j.leukres.2013.12.014. Epub 2013 Dec 25.

18.

[Differential diagnosis of myeloproliferative neoplasms. Quantitative NF-E2 immunohistochemistry for differentiating between essential thrombocythemia and primary myelofibrosis].

Aumann K, Frey AV, May AM, Hauschke D, Kreutz C, Marx JP, Timmer J, Werner M, Pahl HL.

Pathologe. 2013 Nov;34 Suppl 2:201-9. doi: 10.1007/s00292-013-1824-8. German.

PMID:
24196613
19.

Increased leukocyte survival and accelerated onset of lymphoma in the absence of MCL-1 S159-phosphorylation.

Lindner SE, Wissler M, Gründer A, Aumann K, Ottina E, Peintner L, Brauns-Schubert P, Preiss F, Herzog S, Borner C, Charvet C, Villunger A, Pahl HL, Maurer U.

Oncogene. 2014 Oct 30;33(44):5221-4. doi: 10.1038/onc.2013.469. Epub 2013 Nov 11.

20.

Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) study.

Jovanovic JV, Ivey A, Vannucchi AM, Lippert E, Oppliger Leibundgut E, Cassinat B, Pallisgaard N, Maroc N, Hermouet S, Nickless G, Guglielmelli P, van der Reijden BA, Jansen JH, Alpermann T, Schnittger S, Bench A, Tobal K, Wilkins B, Cuthill K, McLornan D, Yeoman K, Akiki S, Bryon J, Jeffries S, Jones A, Percy MJ, Schwemmers S, Gruender A, Kelley TW, Reading S, Pancrazzi A, McMullin MF, Pahl HL, Cross NC, Harrison CN, Prchal JT, Chomienne C, Kiladjian JJ, Barbui T, Grimwade D.

Leukemia. 2013 Oct;27(10):2032-9. doi: 10.1038/leu.2013.219. Epub 2013 Jul 17.

21.

Subcellular mislocalization of the transcription factor NF-E2 in erythroid cells discriminates prefibrotic primary myelofibrosis from essential thrombocythemia.

Aumann K, Frey AV, May AM, Hauschke D, Kreutz C, Marx JP, Timmer J, Werner M, Pahl HL.

Blood. 2013 Jul 4;122(1):93-9. doi: 10.1182/blood-2012-11-463257. Epub 2013 May 13.

22.

MPN patients harbor recurrent truncating mutations in transcription factor NF-E2.

Jutzi JS, Bogeska R, Nikoloski G, Schmid CA, Seeger TS, Stegelmann F, Schwemmers S, Gründer A, Peeken JC, Gothwal M, Wehrle J, Aumann K, Hamdi K, Dierks C, Kamar Wang W, Döhner K, Jansen JH, Pahl HL.

J Exp Med. 2013 May 6;210(5):1003-19.

23.

Transcription factor nuclear factor erythroid-2 mediates expression of the cytokine interleukin 8, a known predictor of inferior outcome in patients with myeloproliferative neoplasms.

Wehrle J, Seeger TS, Schwemmers S, Pfeifer D, Bulashevska A, Pahl HL.

Haematologica. 2013 Jul;98(7):1073-80. doi: 10.3324/haematol.2012.071183. Epub 2013 Feb 26.

25.

Haematopoietic stem cell survival and transplantation efficacy is limited by the BH3-only proteins Bim and Bmf.

Labi V, Bertele D, Woess C, Tischner D, Bock FJ, Schwemmers S, Pahl HL, Geley S, Kunze M, Niemeyer CM, Villunger A, Erlacher M.

EMBO Mol Med. 2013 Jan;5(1):122-36. doi: 10.1002/emmm.201201235. Epub 2012 Nov 24.

26.

Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs.

Emanuel RM, Dueck AC, Geyer HL, Kiladjian JJ, Slot S, Zweegman S, te Boekhorst PA, Commandeur S, Schouten HC, Sackmann F, Kerguelen Fuentes A, Hernández-Maraver D, Pahl HL, Griesshammer M, Stegelmann F, Doehner K, Lehmann T, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto JC, Ranta D, Roy L, Cahn JY, Harrison CN, Radia D, Muxi P, Maldonado N, Besses C, Cervantes F, Johansson PL, Barbui T, Barosi G, Vannucchi AM, Passamonti F, Andreasson B, Ferrari ML, Rambaldi A, Samuelsson J, Birgegard G, Tefferi A, Mesa RA.

J Clin Oncol. 2012 Nov 20;30(33):4098-103. doi: 10.1200/JCO.2012.42.3863. Epub 2012 Oct 15. Erratum in: J Clin Oncol. 2012 Dec 20;30(36):4590. Ferarri, Maria L [corrected to Ferrari, Maria L].

27.

Gab2 signaling in chronic myeloid leukemia cells confers resistance to multiple Bcr-Abl inhibitors.

Wöhrle FU, Halbach S, Aumann K, Schwemmers S, Braun S, Auberger P, Schramek D, Penninger JM, Laßmann S, Werner M, Waller CF, Pahl HL, Zeiser R, Daly RJ, Brummer T.

Leukemia. 2013 Jan;27(1):118-29. doi: 10.1038/leu.2012.222. Epub 2012 Aug 3.

PMID:
22858987
28.

Genetic defects in PRC2 components other than EZH2 are not common in myeloid malignancies.

Kroeze LI, Nikoloski G, da Silva-Coelho P, van Hoogen P, Stevens-Linders E, Kuiper RP, Schnittger S, Haferlach T, Pahl HL, van der Reijden BA, Jansen JH.

Blood. 2012 Feb 2;119(5):1318-9. doi: 10.1182/blood-2011-07-365213. No abstract available.

29.

A JAK-in-the-cell cycle.

Pahl HL.

Blood. 2012 Feb 2;119(5):1096-7. doi: 10.1182/blood-2011-11-393462.

30.

A novel murine model of myeloproliferative disorders generated by overexpression of the transcription factor NF-E2.

Kaufmann KB, Gründer A, Hadlich T, Wehrle J, Gothwal M, Bogeska R, Seeger TS, Kayser S, Pham KB, Jutzi JS, Ganzenmüller L, Steinemann D, Schlegelberger B, Wagner JM, Jung M, Will B, Steidl U, Aumann K, Werner M, Günther T, Schüle R, Rambaldi A, Pahl HL.

J Exp Med. 2012 Jan 16;209(1):35-50. doi: 10.1084/jem.20110540. Epub 2012 Jan 9.

31.

p38β-regulated induction of the heat shock response by carbon monoxide releasing molecule CORM-2 mediates cytoprotection in lung cells in vitro.

Schallner N, Schwemmers S, Schwer CI, Froehlich C, Stoll P, Humar M, Pahl HL, Hoetzel A, Loop T, Goebel U.

Eur J Pharmacol. 2011 Nov 16;670(1):58-66. doi: 10.1016/j.ejphar.2011.08.028. Epub 2011 Sep 8.

PMID:
21925493
32.

TNFα facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms.

Fleischman AG, Aichberger KJ, Luty SB, Bumm TG, Petersen CL, Doratotaj S, Vasudevan KB, LaTocha DH, Yang F, Press RD, Loriaux MM, Pahl HL, Silver RT, Agarwal A, O'Hare T, Druker BJ, Bagby GC, Deininger MW.

Blood. 2011 Dec 8;118(24):6392-8. doi: 10.1182/blood-2011-04-348144. Epub 2011 Aug 22.

33.

Regulation of the adaptor molecule LAT2, an in vivo target gene of AML1/ETO (RUNX1/RUNX1T1), during myeloid differentiation.

Duque-Afonso J, Solari L, Essig A, Berg T, Pahl HL, Lübbert M.

Br J Haematol. 2011 Jun;153(5):612-22. doi: 10.1111/j.1365-2141.2011.08586.x. Epub 2011 Apr 13.

PMID:
21488857
34.

Of mice and men: human RNA polymerase III promoter U6 is more efficient than its murine homologue for shRNA expression from a lentiviral vector in both human and murine progenitor cells.

Roelz R, Pilz IH, Mutschler M, Pahl HL.

Exp Hematol. 2010 Sep;38(9):792-7. doi: 10.1016/j.exphem.2010.05.005. Epub 2010 May 26.

PMID:
20685233
35.

AML1 is overexpressed in patients with myeloproliferative neoplasms and mediates JAK2V617F-independent overexpression of NF-E2.

Wang W, Schwemmers S, Hexner EO, Pahl HL.

Blood. 2010 Jul 15;116(2):254-66. doi: 10.1182/blood-2009-11-254664. Epub 2010 Mar 25.

36.

Krüppel-like factor 15 regulates BMPER in endothelial cells.

Helbing T, Volkmar F, Goebel U, Heinke J, Diehl P, Pahl HL, Bode C, Patterson C, Moser M.

Cardiovasc Res. 2010 Feb 1;85(3):551-9. doi: 10.1093/cvr/cvp314. Epub 2009 Sep 17.

37.

Clinical and hematological presentation of children and adolescents with polycythemia vera.

Cario H, McMullin MF, Pahl HL.

Ann Hematol. 2009 Aug;88(8):713-9. doi: 10.1007/s00277-009-0758-y. Epub 2009 May 26. Review.

38.

NF-E2 overexpression delays erythroid maturation and increases erythrocyte production.

Mutschler M, Magin AS, Buerge M, Roelz R, Schanne DH, Will B, Pilz IH, Migliaccio AR, Pahl HL.

Br J Haematol. 2009 Jul;146(2):203-17. doi: 10.1111/j.1365-2141.2009.07742.x. Epub 2009 May 19.

39.

Protective effects of inhaled carbon monoxide in pig lungs during cardiopulmonary bypass are mediated via an induction of the heat shock response.

Goebel U, Mecklenburg A, Siepe M, Roesslein M, Schwer CI, Pahl HL, Priebe HJ, Schlensak C, Loop T.

Br J Anaesth. 2009 Aug;103(2):173-84. doi: 10.1093/bja/aep087. Epub 2009 Apr 29.

40.

JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms.

Jones AV, Chase A, Silver RT, Oscier D, Zoi K, Wang YL, Cario H, Pahl HL, Collins A, Reiter A, Grand F, Cross NC.

Nat Genet. 2009 Apr;41(4):446-9. doi: 10.1038/ng.334. Epub 2009 Mar 15.

41.

Clinical and molecular characterisation of a prospectively collected cohort of children and adolescents with polycythemia vera.

Cario H, Schwarz K, Herter JM, Komrska V, McMullin MF, Minkov M, Niemeyer C, Pospisilova D, Reinhard H, Debatin KM, Pahl HL.

Br J Haematol. 2008 Aug;142(4):622-6. doi: 10.1111/j.1365-2141.2008.07220.x. Epub 2008 Jun 28.

42.

Carbon monoxide inhalation reduces pulmonary inflammatory response during cardiopulmonary bypass in pigs.

Goebel U, Siepe M, Mecklenburg A, Stein P, Roesslein M, Schwer CI, Schmidt R, Doenst T, Geiger KK, Pahl HL, Schlensak C, Loop T.

Anesthesiology. 2008 Jun;108(6):1025-36. doi: 10.1097/ALN.0b013e3181733115.

PMID:
18497603
43.

Activation of cellular death programs associated with immunosenescence-like phenotype in TPPII knockout mice.

Huai J, Firat E, Nil A, Million D, Gaedicke S, Kanzler B, Freudenberg M, van Endert P, Kohler G, Pahl HL, Aichele P, Eichmann K, Niedermann G.

Proc Natl Acad Sci U S A. 2008 Apr 1;105(13):5177-82. doi: 10.1073/pnas.0801413105. Epub 2008 Mar 24.

44.

Sevoflurane-mediated activation of p38-mitogen-activated stresskinase is independent of apoptosis in Jurkat T-cells.

Roesslein M, Frick M, Auwaerter V, Humar M, Goebel U, Schwer C, Geiger KK, Pahl HL, Pannen BH, Loop T.

Anesth Analg. 2008 Apr;106(4):1150-60, table of contents. doi: 10.1213/ane.0b013e3181683d37.

PMID:
18349187
45.

Thiopental protects human T lymphocytes from apoptosis in vitro via the expression of heat shock protein 70.

Roesslein M, Schibilsky D, Muller L, Goebel U, Schwer C, Humar M, Schmidt R, Geiger KK, Pahl HL, Pannen BH, Loop T.

J Pharmacol Exp Ther. 2008 Apr;325(1):217-25. doi: 10.1124/jpet.107.133108. Epub 2008 Jan 24.

46.

Thionamides inhibit the transcription factor nuclear factor-kappaB by suppression of Rac1 and inhibitor of kappaB kinase alpha.

Humar M, Dohrmann H, Stein P, Andriopoulos N, Goebel U, Roesslein M, Schmidt R, Schwer CI, Loop T, Geiger KK, Pahl HL, Pannen BH.

J Pharmacol Exp Ther. 2008 Mar;324(3):1037-44. Epub 2007 Nov 30.

47.

Repression of T-cell function by thionamides is mediated by inhibition of the activator protein-1/nuclear factor of activated T-cells pathway and is associated with a common structure.

Humar M, Dohrmann H, Stein P, Andriopoulos N, Goebel U, Heimrich B, Roesslein M, Schmidt R, Schwer CI, Hoetzel A, Loop T, Pahl HL, Geiger KK, Pannen BH.

Mol Pharmacol. 2007 Dec;72(6):1647-56. Epub 2007 Sep 18.

48.

JAK2V617F-negative ET patients do not display constitutively active JAK/STAT signaling.

Schwemmers S, Will B, Waller CF, Abdulkarim K, Johansson P, Andreasson B, Pahl HL.

Exp Hematol. 2007 Nov;35(11):1695-703. Epub 2007 Aug 30.

49.

The mitogen-activated protein kinase p38 regulates activator protein 1 by direct phosphorylation of c-Jun.

Humar M, Loop T, Schmidt R, Hoetzel A, Roesslein M, Andriopoulos N, Pahl HL, Geiger KK, Pannen BH.

Int J Biochem Cell Biol. 2007;39(12):2278-88. Epub 2007 Jul 1.

PMID:
17689131
50.

Molecular genetic analyses in familial and sporadic congenital primary erythrocytosis.

Rives S, Pahl HL, Florensa L, Bellosillo B, Neusuess A, Estella J, Debatin KM, Kohne E, Schwarz K, Cario H.

Haematologica. 2007 May;92(5):674-7.

Supplemental Content

Support Center